Clearwater Analytics Buys Enfusion in $1.5 Bln Deal

Dow Jones
01-13
 

By Robb M. Stewart

 

Clearwater Analytics struck a deal to buy software company Enfusion in a deal worth $1.5 billion, bolstering its efforts to build a cloud platform for the investment-management industry.

The companies have signed a definitive agreement offering Enfusion shareholders the equivalent of $11.25 a share in cash and stock, marking a 13% premium to the last closing price and 32% above where Enfusion was trading in September before media reports suggesting a potential sale.

Clearwater is expected to pay about $760 million in cash and issue between roughly 23 million and 28 million new shares to Enfusion shareholders. The company also will pay a further $30 million to retire Enfusion's tax receivable agreement.

With a merger of the software companies, Enfusion's front-office capabilities would be integrated with Clearwater's middle and back-office solutions and client-reporting capabilities. That, Clearwater said, will allow clients to avoid error-prone data handoff that happens between the front, middle and back office, which can create reconciliation issues resulting in inefficiencies, inaccuracies and increased risk.

Clearwater said it expects considerable efficiencies in general and administrative expenses, yielding about $20 million in cost savings that should be delivered over the first two and a half years after the close.

The deal is expected to close in the second quarter, subject to approval from regulators and Enfusion's shareholders. The agreement has been unanimously approved by a special committee of Enfusion directors independent of the company's tax receivable agreement holders, as well as by the boards of both companies.

Enfusion forecast preliminary 2024 revenue was about $201 million to $202 million, representing growth on the year before of 15% to 16%.

The planned tie-up comes after Clearwater last April closed a deal to buy financial services firm Wilshire Advisors for roughly $40 million.

 

Write to Robb M. Stewart at robb.stewart@wsj.com

 

(END) Dow Jones Newswires

January 13, 2025 07:09 ET (12:09 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10